No Data
No Data
Anavex Life Sciences Analyst Ratings
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40
Express News | Anavex Life Sciences Corp - Data From Part B Expected in First Half of 2025
Express News | Anavex Life Sciences Corp - Anavex(®)3-71 Well Tolerated, No Serious Adverse Events
Express News | Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results From Ongoing Phase 2 Study of Anavex®3-71 for the Treatment of Schizophrenia
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results From Ongoing Phase 2 Study of ANAVEX3-71 for the Treatment of Schizophrenia